ClinicalTrials.gg
CompletedNCT03000712Updated Jan 29, 2021

Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.

An interventional study of Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml in Degenerative Arthritis and Knee Osteoarthritis, sponsored by R-Bio. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-29.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's listed conditions name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by R-Bio · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.

Enrollment
78th of 85
26 · median 124
Started
2016
with 4 others
No phase
26 of 96
6 open now
Registered
46th of 96
by date
Lead sponsor
5 of 96
R-Bio

Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 78th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2016, is one of 26 with no phase, and was the 46th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of intra-articular injection of autologous adipose tissue derived mesenchymal stem cells compared after high tibial osteotomy to negative control in the osteoarthritis patients

Read the detailed description

In this clinical trial, the investigational product is administered intra-articularly at 1 week after high tibial osteotomy in a patient with degenerative arthritis of the medial side.

The investigational product is autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissue and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.

It primarily aims to regenerate cartilage, to improve pain and joint function. The intra-articular injection of the investigational product is expected to stimulate the regeneration and growth of cartilage, and to innovatively improve pain and joint function with cartilage regeneration compared to high tibial osteotomy alone.

03

Conditions studied

  • Degenerative Arthritis
  • Knee Osteoarthritis

Browse trials for

Keywords

  • adipose tissue derived mesenchymal stem cell
  • osteoarthritis
  • degenerative arthritis
  • kyung hee university hospital
  • biostar
  • Rbio
  • Osteoarthritis, Knee
  • High tibial osteotomy
  • Joint Diseases
04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 26 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

R-Bio is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must consent in writing to participate in the study by signing and dating an document
  2. Patients who can communicate (exclusion of anyone who cannot understand the questionnaire)
  3. between 20 years and 80 years of age
  4. ≤30
  5. Diagnosis of osteoarthritis by radiographic criteria of Kellgren and Lawrence grade 2-4
  6. Diagnosis of osteoarthritis by ACR(American College of Rheumatology Criteria) Global functional criteria : There is the pain of the knee and radiographic osteophyte and at least one of the following (1) age >50 years (2) Less than 30 minutes of morning stiffness (3) The friction When moving weighted the knee
  7. Patients who agree with
  8. Patients who agree to stop the existing osteoarthritis treatment and to get enough until medication time
  9. Patients scheduled for High tibial osteotomy due to medial gonarthrosis

Exclusion criteria

Exclusion Criteria:

  1. patients with osteoporosis
  2. Preparing for Pregnancy or Pregnant women or lactating mothers.
  3. Patients with positive human immunodeficiency (), (HBV), (HCV), venereal disease research laboratory(VDRL)
  4. Patients with to investigator product or product component or those with a history
  5. Patients who had participated in other clinical trials within 12 weeks prior to this study
  6. Patients who received any drug by intra-articular injection for treatment within 2 months prior to this enrollment.
  7. Patients who experienced as the knee joint cartilage and stem cell therapy or failure to treat
  8. Patents who started or changed the physical therapy program established within 2 weeks before the start of the study or during the study(An established physical therapy program may continue for the duration of the trial, provided that it does not change in frequency and intensity)
  9. Patents included in the following specific risk groups that may influence safety and efficacy assessments at the discretion of the investigator:: septic arthtritis, rheumatic disease, gout, recurrent pseudogout, paget disease, joint fracture, alcaptonuria, acromegaly, hemochromatosis, wilson's disease, primary osteochondrosis, hereditary disorder(ex: hyperkinesia), collagen gene abnormality ,etc
  10. Patients who have severe medical illnesses judged the principal investigator
  11. Patients who have been diagnosed with within 5 years before screening (except for patients who were completely remissioned three years before screening criteria)
  12. Patients who the principal investigator consider inappropriate for the clinical trial due to any other reasons
  13. Patients who received concomitant and who have not passed the prescribed before participating in the clinical trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Autologous Adipose Tissue derived MSCs

    Biological: Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)

    Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml

  • No intervention
    No treatment

    No treatment (after high tibial osteotomy)

Interventions

  • BiologicalAutologous Adipose Tissue derived MSCs 1x10^8cells/3ml

    biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution

    Also known as: JOINTSTEM

07

What researchers measure

Primary outcomes

  1. MRI scan

    MRI perform to measure cartilage defect size change from baseline up to 27 weeks

    Time frame: 24 months

Secondary outcomes

  1. MRI scan

    MRI perform to measure cartilage defect size change from baseline up to 15 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  2. WOMAC score

    Change in WOMAC Total score from baseline up to 15, 27 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  3. WOMAC sub-scale

    Change in WOMAC sub-scale from baseline up to 15, 27 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  4. Kellgren & Lawrence grade

    Change in Kellgren \& Lawrence grade from baseline up to 15, 27 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  5. EQ5D

    Change in the score of EQ-5D from baseline up to 15, 27 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  6. ROM

    change from baseline in knee flexion Range of Motion(ROM) at 15,27 weeks by physical examination

    Time frame: 15, 27 weeks, 18, 24 months

  7. KOOS (Knee Injury & Osteoarthritis Outcome Score)

    Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: 15, 27 weeks, 18, 24 months

  8. PGIC(Patient Global Impression of Change)

    The percentage of subjects who were evaluated as improved at 15 weeks and 27 weeks in the patient global impression of change

    Time frame: 15, 27 weeks, 18, 24 months

  9. PSQI(Pittsburgh Sleep Quality Index)

    Change in PSQI from baseline up to 15, 27 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  10. Biomarkers

    Change from baseline in Biomarkers up to 15, 27 weeks

    Time frame: 15, 27 weeks, 18, 24 months

  11. Incidence of adverse reactions and characteristics associated with investigational product

    Time frame: 15, 27 weeks, 18, 24 months

08

Study locations

1 site
  • KyungHee University Gangdong Hospital
    Seoul, 134-727, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in May 2020, 42 months.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 42 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2016
First posted
Dec 22, 2016
StartActual
Nov 2, 2016
Primary completionActual
May 22, 2020
CompletionActual
May 22, 2020
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03000712
Lead sponsor
R-Bio
Responsible party
Sponsor
First posted
Dec 22, 2016
Start date
Nov 2, 2016
Primary completion
May 22, 2020
Completion
May 22, 2020
Last update
Jan 29, 2021

Study contacts

KANGIL KIM, M.D., Ph.D
principal investigator · KyungHee University Gangdong Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion